Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;34(5):408-418.
doi: 10.37201/req/035.2021. Epub 2021 Apr 28.

[COVID-19 vaccination: the reality after clinical trials]

[Article in Spanish]
J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, J Gómez-Pavón, J González Del Castillo, T Hernández-Sampelayo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, E Bouza  1
Affiliations
Review

[COVID-19 vaccination: the reality after clinical trials]

[Article in Spanish]
J Ruiz-Galiana et al. Rev Esp Quimioter. 2021 Oct.

Abstract
in English, Spanish

After the start of vaccination against SARS-CoV-2, enough clinical experience is already accumulating, in the real world and outside clinical trials, to resolve some of the questions that are still pending about this problem. The Scientific Committee on COVID-19 of the Madrid College of Physicians has discussed and reviewed some of these issues with a multidisciplinary approach. The following document is an attempt to answer some of these questions with the information available so far. This document is structured in questions on different aspects of the indications, efficacy and tolerance of anti-COVID-19 vaccination.

Tras el comienzo de la vacunación frente a SARS-CoV-2, se está acumulando ya suficiente experiencia clínica, en el mundo real y fuera de los ensayos clínicos, para resolver algunas de las cuestiones que siguen pendientes sobre este problema. El Comité Científico sobre COVID-19 del Colegio de Médicos de Madrid ha discutido y revisado algunos de estos temas con una aproximación multidisciplinar. El documento que sigue es un intento de responder a algunas de dichas cuestiones con la información disponible hasta el momento. Este documento se ha estructurado en preguntas sobre distintos aspectos de las indicaciones, eficacia y tolerancia de la vacunación anti-COVID-19.

Keywords: COVID-19; adverse events; indication; tolerance; vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • COVID-19: On the threshold of the fifth year. The situation in Spain.
    Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, García de Viedma D, Bouza E. Rodríguez-Artalejo FJ, et al. Rev Esp Quimioter. 2024 Feb;37(1):17-28. doi: 10.37201/req/123.2023. Epub 2023 Nov 27. Rev Esp Quimioter. 2024. PMID: 38009431 Free PMC article. Review.

References

    1. Hall V, Foulkes S, Charlett A, et al. . Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study). England: June to November 2020 medRxiv 2021011321249642 doi: 10.1101/2021011321249642. - DOI
    1. Anónimo . Duration of immunity and reinfection following SARSCoV-2 infection [Internet], Dublín: reinfection-following-SARSCoV-2-infection.pdf.Health Information and Quality Authority (HIQA); 11 November 2020 [Consultado 5 Dic 2020] Disponible en: https://wwwhiqaie/sites/default/files/2020-11/Advice_Duration-of-immunit.... DOI:
    1. Pilz S, Chakeri A, Ioannidis JP, Richter L, Theiler-Schwetz V, Trummer C, et al. . SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021;51(4):e13520. DOI: 10.1111/eci.13520 - DOI - PMC - PubMed
    1. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529). DOI: 10.1126/science.abf4063 - DOI - PMC - PubMed
    1. van der Hoek L. SARS-CoV-2 Re-infections: Lessons from Other Coronaviruses. Med (N Y). 2020;1(1):23-8. DOI: 10.1016/j.medj.2020.12.005 - DOI - PMC - PubMed

Substances